



Orion Interim Report January-March 2026

23 April 2026



Disclaimer

This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company's future activities and performance. They include statements about future strategies and anticipated benefits of these strategies.

These statements are subject to risks and uncertainties. Actual results may differ substantially from those stated in any forward-looking statement. This is due to a number of factors, including the possibility that Orion may decide not to implement these strategies and the possibility that the anticipated benefits of implemented strategies are not achieved. Orion assumes no obligation to update or revise any information included in this presentation.

All the figures in this presentation have been rounded, which is why the total sums of individual figures may differ from the total sums shown.


Q1 2026 Highlights

- Solid performance across all businesses
- Mr. Berkeley Vincent appointed Executive Vice President, Innovative Medicines and a member of Orion Executive Team as of 8 April 2026
- ODM-212 granted orphan drug designation in mesothelioma by FDA
- Initiation of TEADCO Phase 1b/2 basket trial evaluating ODM-212 in combination with standard of care treatments in patients with select advanced solid tumours




Q1 2026 Financial highlights

Net sales, EUR million




Operating profit, EUR million


Operating profit margin
27.5% (22.0%)



Earnings per share, EUR




Net sales bridge (MEUR)




1	Innovative Medicines	4	Animal Health
2	Branded Products	5	Fermion
3	Generics and Consumer Health	6	Translation differences and other operations

Operating profit bridge (MEUR)




1	Change in sales volume	4	Milestones
2	Changes in prices, COGS, product mix and FX	5	Other operating income and expenses
3	Royalties	6	Fixed costs


Innovative Medicines



Nubeqa® sales (MEUR)




Branded Products




- Easyhaler® budesonide-formoterol the growth driver for the respiratory therapy area
- Recent changes in treatment guidelines favor the use of combination products over monoproducts
- Growth momentum for Women's Health therapy area continues

Generics and Consumer Health



- Steady growth for both generic prescription drugs and consumer health products



Animal Health



- The growth came from multiple products and different geographic regions

TOP 10 products and net sales split in Q1 2026

	Product or product portfolio	EUR million	vs. 2025
1.	Nubeqa®	144.9	+58.4%
2.	Easyhaler® product portfolio	48.3	+7.0%
3.	Entacapone products ¹	21.0	-1.2%
4.	Dexdomitor®, Domitor®, Domosedan®, Antisedan®	9.8	+10.9%
5.	Divina® series	8.2	+14.9%
6.	Burana®	5.4	-5.8%
7.	Trexan®	4.7	+21.3%
8.	Quetiapine products	3.4	+12.0%
9.	Fareston®	3.2	+41.4%
10.	Simdax®	3.0	-29.3%



Innovative Medicines	Branded Products	Animal Health
Generics and Consumer Health	¹ Stalevo®, Comtess®, Comtan® and other entacapone products	

Orion Pharma's key clinical development pipeline



Invented by	Developer(s)	Trial/compound	Indication	Phase I	Phase II	Phase III
		ARASTEP (darolutamide)	prostate cancer (BCR ²)	[Progress bar]		
		DASL-HiCaP (darolutamide)	(Neo-)adjuvant prostate cancer	[Progress bar]		
		OMAHA-003 (opevesostat)	prostate cancer (later-line mCRPC ³)	[Progress bar]		
		OMAHA-004 (opevesostat)	prostate cancer (front-line mCRPC ³)	[Progress bar]		
		LEVEL (TNX-103/levosimendan)	PH-HFpEF ⁴	[Progress bar]		
		LEVEL-2 (TNX-103/levosimendan)	PH-HFpEF ⁴	[Progress bar]		
		MK-5684-01A (opevesostat)	prostate cancer (mCRPC ³)	[Progress bar]		
		OMAHA-015 (opevesostat)	breast, endometrial and ovarian cancers	[Progress bar]		
		CYPIDES (opevesostat) ¹	prostate cancer (later-line mCRPC ³)	[Progress bar]		
		TEADES (ODM-212)	MPM ⁵ , EHE ⁶ and other solid tumors	[Progress bar]		
		TEADCO (ODM-212)	mesothelioma, NSCLC ⁷ and pancreatic cancer	Phase 1b/2		

¹ study started prior license agreement with MSD and thus Orion is conducting and will complete the trial

² biochemical recurrence


³ metastatic castration-resistant prostate cancer

⁴ pulmonary hypertension in heart failure with preserved ejection fraction

⁵ malignant pleural mesothelioma

⁶ epithelioid hemangioendothelioma

⁷ non-small cell lung cancer with KRAS G12C mutation



Changes vs. Q4'2025: TEADCO Phase 2 program initiated.

Sustainability reporting and performance 2025

Orion Pharma publishes its Sustainability statement as a part of the Financial statement documents in accordance with the sustainability reporting requirements of the European Sustainability Reporting Standards (ESRS).

Key highlights

-13%



Greenhouse gas emissions reduction¹ (Scope 1&2)

4.9

LTIF²

Injury rate



98%



Code of Conduct training coverage³

96%



Supplier adherence to the Third Party Code of Conduct⁴

¹ from 2024

² LTIF = lost time injury frequency

³ of all employees

⁴ Orion Pharma's active suppliers of packaging materials, raw materials, and products confirmed their adherence to the Third Party Code of Conduct (% by spend)

Outlook for 2026 (specified on 23 April 2026)

Net sales

EUR 1,950 million–EUR 2,100 million

Operating profit

EUR 600 million–EUR 750 million



Upcoming events

Half-Year Financial Report 1–6/2026
Interim Report 1–9/2026

17/7/2026
28/10/2026

